Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults

NCT03357614 is registered in ClinicalTrials.gov with Iterum Therapeutics, International Limited as lead sponsor.

NCT NCT03357614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03357614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults
Lead sponsor
Iterum Therapeutics, International Limited
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2018
Completion date
December 14, 2019
Enrollment
1,395 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

complicated urinary tract infections